Lawrence A Kenyon's Net Worth
$553 Thousand
Who is Lawrence A Kenyon?
Lawrence A Kenyon does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include ALFACELL CORP, Outlook Therapeutics, Inc., PAR PHARMACEUTICAL COMPANIES, INC., Arno Therapeutics, Inc, and NEOPHARM INC.
SEC CIK
Lawrence A Kenyon's CIK is 0001230484
Past Insider Trading and Trends
2007 was Lawrence A Kenyon's most active year for acquiring shares with 7 total transactions. Lawrence A Kenyon's most active month to acquire stocks was the month of March. 2010 was Lawrence A Kenyon's most active year for disposing of shares, totalling 21 transactions. Lawrence A Kenyon's most active month to dispose stocks was the month of February. 2004 saw Lawrence A Kenyon paying a total of $398,200.00 for 20,000 shares, this is the most they've acquired in one year. In 2010 Lawrence A Kenyon cashed out on 50,087 shares for a total of $733,362.11, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
ALFACELL CORP No price found
President, CEO and CFOLawrence A Kenyon owns 25,000 units of Common Stock. In the year 2007 Lawrence A Kenyon filed a total of 5 filings.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 23
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
|
∞
| 25K |
$2.14 | $53,381.32 | 25K |
Apr 11
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 16
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Outlook Therapeutics, Inc. (OTLK) Snapshot price: $7.95
CHIEF FINANCIAL OFFICERLawrence A Kenyon owns 18,926 units of Common Stock which is worth $150,461.70. From 2016 to 2024 Lawrence A Kenyon acquired a total of 85,000 shares in Outlook Therapeutics, Inc. at a cost of $40,680.00, Lawrence also disposed a total of 38,965 shares of Outlook Therapeutics, Inc. equalling to $42,963.65.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 20
| |||
Form 4
| +112.03% | 10K |
$1.83 | $18,300.00 | 18.93K |
Apr 20
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 17
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 19
| |||
Form 4/A
| -13.14% | -1.35K |
$1.70 | -$2,295.00 | 8.93K |
Sep 18
| |||
Form 4
| -1.64% | -1.35K |
$1.70 | -$2,295.00 | 80.86K |
Sep 18
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 12
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 19
| |||
Form 4
| +43.70% | 25K |
$0.90 | $22,380.00 | 82.21K |
Feb 7
| |||
Form 4
| -15.00% | -10.10K |
$0.87 | -$8,807.20 | 57.21K |
Sep 18
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 1
| |||
Form 4
| -27.99% | -26.16K |
$1.13 | -$29,566.45 | 67.31K |
Dec 22
| |||
Form 4
| +115.00% | 50K |
—
|
—
| 93.48K |
Dec 21
| |||
Form 3/A
|
—
|
0
|
—
|
—
|
0
| ||||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
PAR PHARMACEUTICAL COMPANIES, INC. No price found
EVP, Chief Financial OfficerLawrence A Kenyon owns 14,337 units of Common Stock.acquired a total of 42,985 shares in PAR PHARMACEUTICAL COMPANIES, INC. at a cost of $279,993.34, Lawrence also disposed a total of 28,648 shares of PAR PHARMACEUTICAL COMPANIES, INC. equalling to $733,362.11.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| -30.57% | -6.31K |
$26.90 | -$169,792.80 | 14.34K |
Aug 2
| |||
Form 4
|
—
|
0
|
$19.13 | -$260,361.62 | 20.65K |
Mar 3
| |||
Form 4
| -4.16% | -897.00 |
$25.88 | -$23,214.36 | 20.65K |
Jan 8
| |||
Form 4/A
|
—
|
0
|
—
|
—
|
0
|
Jan 4
| |||
Form 4
| +100.99% | 10.83K |
—
|
—
| 21.55K |
Jan 4
| |||
Form 4
|
∞
| 10.72K |
—
|
—
| 10.72K |
Jan 8
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Arno Therapeutics, Inc No price found
Chief Financial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 24
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
NEOPHARM INC No price found
CFO and Secretary
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 25
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 28
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 17
| |||
No matching records found |